Yuexian Xing
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuexian Xing has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Fang Jia
Department of Cardiovascular Medicine, the Third Affiliated Hospital of Soochow University, Changzhou, China
1 shared publicationJingru Wang
Department of Endocrinology, The Third Affiliated Hospital of Soochow University, Changzhou, China
1 shared publicationKaiming Luo
Department of Endocrinology, The Third Affiliated Hospital of Soochow University, Changzhou, China
1 shared publication- Long Wang
The Third Affiliated Hospital of Soochow University
1 shared publication Man Li
Department of Endocrinology, The Third Affiliated Hospital of Soochow University, Changzhou, China
1 shared publicationShoukui Xiang
Department of Endocrinology, the Third Affiliated Hospital of Soochow University, Changzhou, China.
1 shared publication
Latest Publications
- 23 January 2026
- p. 25038
Exploring the potential application of roxadustat in chronic kidney disease-related osteoporosis based on the regulatory role of HIF-1α in bone metabolism.
Oxygen is an essential element in the process of cellular oxidation, and hypoxia, a state of insufficient oxygen, can profoundly influence cellular adaptive responses through gene transcription, thereby impacting cell metabolism, angiogenesis, and inflammation. Hypoxia-inducible factor (HIF), particularly its alpha subunit (HIF-1α), is a critical transcription factor that orchestrates cellular adaptation to hypoxic environments and plays a multifaceted role in various cellular activities. In recent years, HIF-1α has been widely implicated in stimulating hematopoietic function and the good effect of roxadustat in treating renal anemia. However, the specific role of HIF-1α in bone metabolism remains unclear. More and more studies have shown that HIF-1α can not only directly affect osteoblasts, osteoclasts, osteocytes, and bone matrix during bone remodeling, but also locally and remotely regulate macrophages and various cytokines involved in bone remodeling. In addition, HIF-1α can indirectly regulate bone metabolism by promoting angiogenesis and regulating cell metabolism. This review comprehensively elucidates the intricate mechanisms by which HIF-1α influences bone metabolism. The aim is to provide a robust theoretical foundation for exploring the potential therapeutic application of roxadustat to improve bone metabolism in patients with Chronic Kidney Disease-related Osteoporosis (CKD-RO). It is important to note that, while this review highlights promising findings, the current evidence is primarily derived from preclinical animal studies and necessitates rigorous clinical validation.
- 23 January 2026
- p. 25038
Exploring the potential application of roxadustat in chronic kidney disease-related osteoporosis based on the regulatory role of HIF-1α in bone metabolism.
Oxygen is an essential element in the process of cellular oxidation, and hypoxia, a state of insufficient oxygen, can profoundly influence cellular adaptive responses through gene transcription, thereby impacting cell metabolism, angiogenesis, and inflammation. Hypoxia-inducible factor (HIF), particularly its alpha subunit (HIF-1α), is a critical transcription factor that orchestrates cellular adaptation to hypoxic environments and plays a multifaceted role in various cellular activities. In recent years, HIF-1α has been widely implicated in stimulating hematopoietic function and the good effect of roxadustat in treating renal anemia. However, the specific role of HIF-1α in bone metabolism remains unclear. More and more studies have shown that HIF-1α can not only directly affect osteoblasts, osteoclasts, osteocytes, and bone matrix during bone remodeling, but also locally and remotely regulate macrophages and various cytokines involved in bone remodeling. In addition, HIF-1α can indirectly regulate bone metabolism by promoting angiogenesis and regulating cell metabolism. This review comprehensively elucidates the intricate mechanisms by which HIF-1α influences bone metabolism. The aim is to provide a robust theoretical foundation for exploring the potential therapeutic application of roxadustat to improve bone metabolism in patients with Chronic Kidney Disease-related Osteoporosis (CKD-RO). It is important to note that, while this review highlights promising findings, the current evidence is primarily derived from preclinical animal studies and necessitates rigorous clinical validation.
- Open Access
- 1 January 2023
- Published by AME Publishing Company in AME Case Reports
- Vol. 9, 84
RFX6 heterozygous frame-shift variation causes maturity- onset diabetes mellitus of the young (MODY) with refractory hyperlipidemia: a case report
Case Report RFX6 heterozygous frame-shift variation causes maturity- onset diabetes mellitus of the young (MODY) with refractory hyperlipidemia: a case report Man Li, Long Wang, Yuexian Xing, Xiaolin Huang, Fang Jia, Wendong Xu, Kaiming Luo
- 1 January 2023
- Published by AME Publishing Company in AME Case Reports
- Vol. 9, 84
Open AccessRFX6 heterozygous frame-shift variation causes maturity- onset diabetes mellitus of the young (MODY) with refractory hyperlipidemia: a case report
Case Report RFX6 heterozygous frame-shift variation causes maturity- onset diabetes mellitus of the young (MODY) with refractory hyperlipidemia: a case report Man Li, Long Wang, Yuexian Xing, Xiaolin Huang, Fang Jia, Wendong Xu, Kaiming Luo